Andrew Witty, CEO of GlaxoSmithKline, discusses his company's 2012 earnings and explains why he is optimistic about the company's restructuring plans in Europe.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT